Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gene therapy |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01XL10
|
| gptkbp:brand |
gptkb:Abecma
|
| gptkbp:CASNumber |
2228327-84-6
|
| gptkbp:developer |
gptkb:bluebird_bio
gptkb:Bristol_Myers_Squibb |
| https://www.w3.org/2000/01/rdf-schema#label |
idecabtagene vicleucel
|
| gptkbp:indication |
relapsed or refractory multiple myeloma
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
genetically modified autologous T cells
targets B-cell maturation antigen (BCMA) |
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
infections neutropenia neurotoxicity thrombocytopenia cytokine release syndrome |
| gptkbp:source |
autologous T cells
|
| gptkbp:storage |
cryopreserved
|
| gptkbp:target |
gptkb:BCMA
|
| gptkbp:UNII |
8QX8JX008I
|
| gptkbp:usedFor |
multiple myeloma
|
| gptkbp:bfsParent |
gptkb:Abecma
|
| gptkbp:bfsLayer |
6
|